NICE green lights Roche’s Rozlytrek for NTRK tumours

The UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid tumours, shortly after clearing a rival drug from

UK starts human gene sequencing project to aid COVID-19 figh...

In a landmark study, thousands of NHS patients will have their DNA studied to see how a person’s genetic profile plays a role in susceptibility to COVID-19.

Nine pharma trends for 2020

Sarah Rickwood looks back at how pharma changed over the last decade and what this might mean for the industry in 2020.

Liquid Biopsy Summit 2020

The Liquid Biopsy Summit 2020

Novo extends R&D alliance with AI specialist e-Therapeutics

NHS looks to digital and genomics to secure its future

Genomics, digital tech and artificial intelligence are at the forefront of the government’s long term plan for the NHS, unveiled today.